SG11202109004TA - Human serum albumin in formulations - Google Patents

Human serum albumin in formulations

Info

Publication number
SG11202109004TA
SG11202109004TA SG11202109004TA SG11202109004TA SG11202109004TA SG 11202109004T A SG11202109004T A SG 11202109004TA SG 11202109004T A SG11202109004T A SG 11202109004TA SG 11202109004T A SG11202109004T A SG 11202109004TA SG 11202109004T A SG11202109004T A SG 11202109004TA
Authority
SG
Singapore
Prior art keywords
formulations
serum albumin
human serum
human
albumin
Prior art date
Application number
SG11202109004TA
Inventor
Dorothy Kim
Michael Marlow
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11202109004TA publication Critical patent/SG11202109004TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
SG11202109004TA 2019-03-05 2020-03-03 Human serum albumin in formulations SG11202109004TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962813843P 2019-03-05 2019-03-05
PCT/US2020/020752 WO2020180850A1 (en) 2019-03-05 2020-03-03 Human serum albumin in formulations

Publications (1)

Publication Number Publication Date
SG11202109004TA true SG11202109004TA (en) 2021-09-29

Family

ID=70190088

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202109004TA SG11202109004TA (en) 2019-03-05 2020-03-03 Human serum albumin in formulations

Country Status (13)

Country Link
US (2) US11241499B2 (en)
EP (1) EP3934620A1 (en)
JP (1) JP2022523962A (en)
KR (1) KR20210135543A (en)
CN (1) CN113543811A (en)
AU (1) AU2020232683A1 (en)
BR (1) BR112021015790A2 (en)
CA (1) CA3130457A1 (en)
EA (1) EA202192422A1 (en)
IL (1) IL285938A (en)
MX (1) MX2021010558A (en)
SG (1) SG11202109004TA (en)
WO (1) WO2020180850A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4243769A2 (en) * 2020-11-16 2023-09-20 W. L. Gore & Associates, Inc. Formulations, methods, and pre-filled injection devices without fatty acid particles

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180098625A (en) * 2015-12-30 2018-09-04 제넨테크, 인크. Formulation with reduced degradation of polysorbate

Also Published As

Publication number Publication date
MX2021010558A (en) 2021-10-13
IL285938A (en) 2021-10-31
EP3934620A1 (en) 2022-01-12
US20220118097A1 (en) 2022-04-21
JP2022523962A (en) 2022-04-27
CA3130457A1 (en) 2020-09-10
WO2020180850A1 (en) 2020-09-10
EA202192422A1 (en) 2021-12-09
KR20210135543A (en) 2021-11-15
US11241499B2 (en) 2022-02-08
BR112021015790A2 (en) 2021-10-05
AU2020232683A1 (en) 2021-09-02
CN113543811A (en) 2021-10-22
US20200282063A1 (en) 2020-09-10

Similar Documents

Publication Publication Date Title
IL276464A (en) Methods and compositions for therapeutic protein delivery
EP3464608A4 (en) Therapeutic recombinant klotho proteins and compositions and methods involving the same
HK1248547A1 (en) Pharmaceutical formulations comprising tenofovir and emtricitabine
EP3518971A4 (en) Antibody and protein therapeutic formulations and uses thereof
EP3551212A4 (en) Novel recombinant klotho proteins and compositions and methods involving the same
IL290141A (en) Anti-pvrig antibodies formulations and uses thereof
HK1247244A1 (en) Novel human serum albumin mutant
EP3294286A4 (en) Docetaxel and human serum albumin complexes
SG11202109277WA (en) Stable protein formulations
IL286100A (en) Anti-il-36r antibody formulations
IL286847A (en) Hsp90-binding conjugates and formulations thereof
EP3310375A4 (en) Use of low molecular weight fractions of human serum albumin in treating diseases
ZA202101250B (en) Novel crispr-associated protein and use thereof
EP3716779A4 (en) Formulations for nutritional support in subjects in need thereof
SG11202104912SA (en) Fusion protein and use thereof
EP3902556A4 (en) In vivo engineered cereblon protein
IL277791A (en) Hsp90-targeting conjugates and formulations thereof
SG11202110400QA (en) Fusion protein and use thereof
IL291131A (en) Anti-il-23p19 antibody formulations
ZA202005143B (en) Oral formulations and uses thereof
IL285134A (en) Therapeutic antibody formulation
EP3816181A4 (en) Improved fviii fusion protein and use thereof
IL285938A (en) Human serum albumin in formulations
EP3402510A4 (en) Compositions and formulations including cabazitaxel and human serum albumin
ZA202007491B (en) Stable fusion protein formulation